{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:05:33Z","timestamp":1783908333351,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,12]]},"DOI":"10.7759\/cureus.112541","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:08:32Z","timestamp":1783904912000},"source":"Crossref","is-referenced-by-count":0,"title":["Prolonged Tricyclic Antidepressant Toxicity in a Pediatric Patient: The Importance of Understanding the Multifactorial Nature of Amitriptyline Metabolism"],"prefix":"10.7759","author":[{"given":"Ashleigh W","family":"Navarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Sahhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.86a.19005","article-title":"Beyond depression: other uses for tricyclic antidepressants","volume":"86","author":"Schneider J","year":"2019","unstructured":"Schneider J, Patterson M, Jimenez XF. Beyond depression: other uses for tricyclic antidepressants. Cleve Clin J Med. 2019, 86:807-14. 10.3949\/ccjm.86a.19005","journal-title":"Cleve Clin J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999. 00973.x","article-title":"Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline","volume":"48","author":"Gupta SK","year":"1999","unstructured":"Gupta SK, Shah JC, Hwang SS. Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. Br J Clin Pharmacol. 1999, 48:71-78. 10.1046\/j.1365-2125.1999. 00973.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref3","article-title":"Amitriptyline therapy and CYP2D6 and CYP2C19 genotype","author":"Dean L","year":"2012","unstructured":"Dean L, MD and Kane, M, PhD. Amitriptyline therapy and CYP2D6 and CYP2C19 genotype. Medical Genetics Summaries. Pratt VM, Scott SA, Pirmohamed M, et al. (ed): National Center for Biotechnology Information (US, 2012."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12451","article-title":"A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans","volume":"10","author":"Ryu S","year":"2017","unstructured":"Ryu S, Park S, Lee JH, et al.. A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017, 10:93-101. 10.1111\/cts.12451","journal-title":"Clin Transl Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1023\/a:1006949816036","article-title":"Metabolism of tricyclic antidepressants","volume":"19","author":"Rudorfer MV","year":"1999","unstructured":"Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol. 1999, 19:373-409. 10.1023\/a:1006949816036","journal-title":"Cell Mol Neurobiol"},{"key":"ref6","article-title":"Amitriptyline","author":"Thour A","year":"2023","unstructured":"Thour A, Marwaha R. Amitriptyline. Thour A, Marwaha R (ed): StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref7","article-title":"Tricyclic antidepressant toxicity","author":"Khalid MM","year":"2023","unstructured":"Khalid MM, Waseem M. Tricyclic antidepressant toxicity. Khalid MM, Waseem M (ed): StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/emj.18.4.236","article-title":"Tricyclic antidepressant overdose: a review","volume":"18","author":"Kerr GW","year":"2001","unstructured":"Kerr GW, McGuffie AC, Wilkie S. Tricyclic antidepressant overdose: a review. Emerg Med J. 2001, 18:236-41. 10.1136\/emj.18.4.236","journal-title":"Emerg Med J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259831","article-title":"Tricyclic antidepressant poisoning. Management of arrhythmias","volume":"1","author":"Pentel PR","year":"1986","unstructured":"Pentel PR, Benowitz NL. Tricyclic antidepressant poisoning. Management of arrhythmias. Med Toxicol. 1986, 1:101-21. 10.1007\/BF03259831","journal-title":"Med Toxicol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70415","article-title":"Low-dose cannabidiol increases plasma concentrations of amitriptyline: a clinical drug-drug interaction study","volume":"92","author":"Gorbenko AA","year":"2026","unstructured":"Gorbenko AA, Post TE, Strugala PK, et al.. Low-dose cannabidiol increases plasma concentrations of amitriptyline: a clinical drug-drug interaction study. Br J Clin Pharmacol. 2026, 92:1595-606. 10.1002\/bcp.70415","journal-title":"Br J Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199701000-00016","article-title":"Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants","volume":"36","author":"Wilens TE","year":"1997","unstructured":"Wilens TE, Biederman J, Spencer TJ. Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry. 1997, 36:45-8. 10.1097\/00004583-199701000-00016","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000073","article-title":"Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450","volume":"48","author":"Bansal S","year":"2020","unstructured":"Bansal S, Maharao N, Paine MF, Unadkat JD. Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450. Drug Metab Dispos. 2020, 48:1008-17. 10.1124\/dmd.120.000073","journal-title":"Drug Metab Dispos"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.031","article-title":"Challenges in cardiovascular evaluation and management of obese patients: JACC state-of-the-art review","volume":"81","author":"Bianchettin RG","year":"2023","unstructured":"Bianchettin RG, Lavie CJ, Lopez-Jimenez F. Challenges in cardiovascular evaluation and management of obese patients: JACC state-of-the-art review. J Am Coll Cardiol. 2023, 81:490-504. 10.1016\/j.jacc.2022.11.031","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318237b0fa","article-title":"No influence of body weight on serum levels of antidepressants","volume":"33","author":"Unterecker S","year":"2011","unstructured":"Unterecker S, Deckert J, Pfuhlmann B. No influence of body weight on serum levels of antidepressants. Ther Drug Monit. 2011, 33:730-4. 10.1097\/FTD.0b013e318237b0fa","journal-title":"Ther Drug Monit"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000812","article-title":"Impact of body mass index on serum concentrations of antidepressants and antipsychotics","volume":"43","author":"Warrings B","year":"2021","unstructured":"Warrings B, Samanski L, Deckert J, Unterecker S, Scherf-Clavel M. Impact of body mass index on serum concentrations of antidepressants and antipsychotics. Ther Drug Monit. 2021, 43:286-91. 10.1097\/FTD.0000000000000812","journal-title":"Ther Drug Monit"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/480265-prolonged-tricyclic-antidepressant-toxicity-in-a-pediatric-patient-the-importance-of-understanding-the-multifactorial-nature-of-amitriptyline-metabolism","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:08:33Z","timestamp":1783904913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/480265-prolonged-tricyclic-antidepressant-toxicity-in-a-pediatric-patient-the-importance-of-understanding-the-multifactorial-nature-of-amitriptyline-metabolism"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.112541","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,12]]}}}